Drug intelligence / Profile preview

HY-1770

Development stage: Preclinical
Lead developer: Suzhou Pharmavan Cancer Research Center
Modality: Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

HY-1770 is an investigational multispecific therapeutic candidate, likely a trispecific antibody, being developed by Suzhou Pharmavan Cancer Research Center for the treatment of atopic dermatitis. It is designed to simultaneously target three key inflammatory mediators: Interleukin-17A (IL-17A), Interleukin-17F (IL-17F), and the Interleukin-4 receptor alpha (IL-4Rα) subunit. By inhibiting these pathways, HY-1770 aims to provide a comprehensive blockade of both Th2 (IL-4/IL-13) and Th17 (IL-17) signaling, which are central to the complex inflammatory milieu of atopic dermatitis. The drug is currently in the IND-enabling stage of development.

Targets

IL17F (Interleukin 17F)IL-17A (Interleukin-17A)IL4R (Interleukin-4 receptor alpha subunit)

Beyond the preview

Go deeper on HY-1770.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HY-1770.

Explore the full profile